Cargando…
Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurren...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345083/ https://www.ncbi.nlm.nih.gov/pubmed/35928329 http://dx.doi.org/10.25259/SNI_455_2022 |
_version_ | 1784761353543614464 |
---|---|
author | Katsuki, Masahito Kawamura, Shin Koh, Akihito |
author_facet | Katsuki, Masahito Kawamura, Shin Koh, Akihito |
author_sort | Katsuki, Masahito |
collection | PubMed |
description | BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurrence. However, not all CSDHs are liquid, and some have structures such as trabecula, hematoma, and clots, suggesting oketsu (blood stasis). Therefore, we prospectively investigated the keishibukuryogan (KBG) effectiveness, which treats oketsu, for CSDH recurrence prevention and hematoma resolution compared to GRS. METHODS: We prospectively prescribed KBG 7.5 g/day for 12 CSDH patients after burr-hole surgery. As a control cohort, we retrospectively collected 48 patients treated by GRS 7.5 g/day. The recurrence within 1 month and the hematoma thickness after 1 month were evaluated. RESULTS: The median age was 84 years old. All the patients’ symptoms improved after surgery. The median preoperative midline shift and mean hematoma thicknesses were 6.0 mm and 23.75 mm. Those at 1 month were 2.0 mm and 11.43 mm. The recurrence rate was not significantly different between the KBG cohort (1 of 12) and the GRS cohort (4 of 48) (P = 0.999). The KBG’s noninferiority to GRS regarding the hematoma thickness at 1 month was statistically proven; KBG (12.26 mm) and GRS (11.20 mm). CONCLUSION: The recurrence rate at 1 month was not different between the KBG and GRS cohorts. The hematoma thickness at 1 month in the KBG cohort was not statistically inferior to that in the GRS cohort. |
format | Online Article Text |
id | pubmed-9345083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Scientific Scholar |
record_format | MEDLINE/PubMed |
spelling | pubmed-93450832022-08-03 Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study Katsuki, Masahito Kawamura, Shin Koh, Akihito Surg Neurol Int Original Article BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurrence. However, not all CSDHs are liquid, and some have structures such as trabecula, hematoma, and clots, suggesting oketsu (blood stasis). Therefore, we prospectively investigated the keishibukuryogan (KBG) effectiveness, which treats oketsu, for CSDH recurrence prevention and hematoma resolution compared to GRS. METHODS: We prospectively prescribed KBG 7.5 g/day for 12 CSDH patients after burr-hole surgery. As a control cohort, we retrospectively collected 48 patients treated by GRS 7.5 g/day. The recurrence within 1 month and the hematoma thickness after 1 month were evaluated. RESULTS: The median age was 84 years old. All the patients’ symptoms improved after surgery. The median preoperative midline shift and mean hematoma thicknesses were 6.0 mm and 23.75 mm. Those at 1 month were 2.0 mm and 11.43 mm. The recurrence rate was not significantly different between the KBG cohort (1 of 12) and the GRS cohort (4 of 48) (P = 0.999). The KBG’s noninferiority to GRS regarding the hematoma thickness at 1 month was statistically proven; KBG (12.26 mm) and GRS (11.20 mm). CONCLUSION: The recurrence rate at 1 month was not different between the KBG and GRS cohorts. The hematoma thickness at 1 month in the KBG cohort was not statistically inferior to that in the GRS cohort. Scientific Scholar 2022-07-15 /pmc/articles/PMC9345083/ /pubmed/35928329 http://dx.doi.org/10.25259/SNI_455_2022 Text en Copyright: © 2022 Surgical Neurology International https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Katsuki, Masahito Kawamura, Shin Koh, Akihito Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title | Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title_full | Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title_fullStr | Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title_full_unstemmed | Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title_short | Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study |
title_sort | japanese herbal kampo medicine, keishibukuryogan, for chronic subdural hematoma – prospective observational study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345083/ https://www.ncbi.nlm.nih.gov/pubmed/35928329 http://dx.doi.org/10.25259/SNI_455_2022 |
work_keys_str_mv | AT katsukimasahito japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy AT kawamurashin japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy AT kohakihito japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy |